Catalent

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

CTLT reports Q3 revenue decline, eyes growth in gene therapy

CTLT faced challenges in the Biologics segment and adjusted its fiscal 2023 guidance due to operational and COVID-related issues. However, the company's capacity and healthy pipeline in the gene therapy business present opportunities for growth. The company is also evaluating divestitures to reduce debt load and is focused on improving financial rigor in the upcoming fiscal year.

Catalent reports solid Q2 earnings, eyes gene therapy expansion

Catalent's Q2 performance was solid, with a focus on collaborations, ESG initiatives, and strong market positioning. Challenges in the supply chain and COVID revenue assumptions were notable, but opportunities in gene therapy and core business growth are promising. The company remains optimistic about future growth and strategic partnerships.

Catalent adjusts guidance, targets cost savings amid operational challenges

Catalent focused on improving productivity and cost structure to return to historical margin levels.
Addressing investor concerns on regulatory inspections and confident in corrective actions.
Expecting significant cost savings in fiscal '24 and targeting positive cash generation.
Operational challenges in Q3 impacting financials in Q4, with a focus on improving profitability.

Catalent addresses challenges, eyes growth in gene therapy and GLP-1

Catalent navigated fiscal challenges, focusing on growth areas like gene therapy and GLP-1 projects. The company aims to address financial performance, operational efficiency, and strategic reviews to enhance shareholder value and sustain growth.

Catalent reports solid Q1 performance amidst revenue challenges and growth opportunities

Catalent's Q1 performance was solid despite revenue decline from COVID.
The company is focusing on growth drivers like gene therapy and GLP-1 demand.
Challenges include revenue concentration risks and capacity constraints.
Opportunities lie in new business wins, tech transfer completion, and strategic improvements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 25, 2023 to file lead plaintiff applications in a securities class action lawsuit against Catalent, Inc. (the “Company”) (NYSE: CTLT), if they purchased the Company's securities between August 30, 2021 and October 31, 2022, inclusive (the “Class Period”).

CATALENT SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess Of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Catalent, Inc. - CTLT

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Catalent, Inc. (NYSE: CTLT) between August 30, 2021 and October 31, 2022, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 25, 2023.

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Catalent, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – CTLT

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Catalent business and prospects, resulting in its stock trading at inflated prices.

INVESTOR DEADLINE: Catalent, Inc. Investors with Substantial Losses Have Opportunity to Lead the Catalent Class Action Lawsuit – CTLT

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On August 29, 2022, Catalent disclosed that demand for its COVID-related products was facing substantial headwinds. On this news, Catalent's stock price fell $7.42, or 7.

The Law Offices of Frank R. Cruz Announces Investigation of Catalent, Inc. (CTLT) on Behalf of Investors

SAN DIEGO--(BUSINESS WIRE)---- $CTLT #COVID19--Catalent, Inc.

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Catalent, Inc. (CTLT)

LOS ANGELES--(BUSINESS WIRE)---- $CTLT #CTLT--The Schall Law Firm Encourages Investors in Catalent, Inc.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Catalent, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Labaton Sucharow LLP (“Labaton Sucharow”) announces that, on February 24, 2023, it filed a securities class action lawsuit (the “Complaint”) on behalf of its client City of Warwick Retirement System against Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT) and certain Catalent officers (collectively, “Defendants”). The action, which is captioned City of Warwick Retirement System v. Catalent, Inc., No. 3:23-cv-1108 (D.N.J.

Labaton Sucharow LLP Announces Securities Class Action Lawsuit Filed Against Catalent, Inc. and Certain Executives

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced the appointment of Joseph A. Ferraro as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary. Mr. Ferraro will be responsible for managing Catalent's global legal and compliance operations. He will be based at the company's headquarters in Somerset, New Jersey, head up the company's Legal Leadership Team, and serve on its Executive Leadership Team, reporting directly to Catalent's Executive Vice President and Chief Administrative Officer, Steven Fasman.

Catalent Appoints Joseph A. Ferraro as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary

The shares did exceptionally well considering the company had a ho-hum quarter.

Why Catalent Stock Was on Fire This Week

Align Technology

Carnival

Norwegian Cruise Line

NVIDIA

Royal Caribbean Cruises

SVB Financial Group

Tesla

Warner Bros Discovery Inc

Jim Cramer said that he's intrigued by winners this year like Tesla, Meta Platforms and Nvidia.

Jim Cramer says he's intrigued by these 10 top performing S&P 500 stocks

Catalent, Inc. (NYSE:CTLT ) Q2 2023 Results Conference Call February 7, 2023 8:15 AM ET Company Participants Paul Surdez - Vice President, Investor Relations Alessandro Maselli - President & Chief Executive Officer Tom Castellano - Senior Vice President & Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Dave Windley - Jefferies Max Smock - William Blair Paul Knight - KeyBanc Tejas Savant - Morgan Stanley Sean Dodge - RBC Capital Markets Justin Bowers - Deutsche Bank Derik De Bruin - Bank of America John Sourbeer - UBS Evan Stover - Baird Jack Meehan - Nephron Research Operator Hello, everyone, and welcome to the Catalent, Inc. Second Quarter Fiscal Year 2023 Earnings Conference Call. My name is Emily, and I'll be moderating your call today.

Catalent, Inc. (CTLT) Q2 2023 Earnings Call Transcript

Although the revenue and EPS for Catalent (CTLT) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Compared to Estimates, Catalent (CTLT) Q2 Earnings: A Look at Key Metrics

Catalent (CTLT) records lower revenues in both segments in its second-quarter fiscal 2023, resulting in overall soft performance.

Catalent (CTLT) Q2 Earnings Lag Estimates, Revenues Top

Catalent (CTLT) shares gain significantly, following a Bloomberg report about a potential acquisition of the CDMO company by Danaher, a life sciences company.

Catalent (CTLT) Surges on Rumors of Acquisition by Danaher

Catalent (CTLT) delivered earnings and revenue surprises of -6.94% and 2.41%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) Misses Q2 Earnings Estimates

Catalent, Inc. Reports Second Quarter Fiscal 2023 Results

The stock price of Catalent Inc (NYSE: CTLT) surged by 19.54% today. This is why.

CTLT Stock: 19.54% Surge Explanation

Apple

Amazon

Activision Blizzard

Cisco Systems

Alphabet

KB Home

Newmont Mining

PulteGroup

Tyson Foods

Take-Two Interactive Software

U.S. stock markets opened the trading week with declines on Monday, Feb. 6, on concerns about additional tightening moves by the Federal Reserve.

Markets Drop for Second-Straight Day on Fed Hike Fears

Celsius Holdings

Even as markets were under pressure, market participants found things to be happy about with these two companies.

These 2 Stocks Are Making a Pop on Monday

Danaher

Life Storage

Newcrest Mining Ltd

Public Storage

Mergers and acquisitions are off to a hot start in February as major gold miners and public storage REITs propose $28 billion in deals. The post Takeover News: February Opens With M&A Bang As Gold Miners, REITs Pitch $28 Billion In Deals appeared first on Investor's Business Daily.

Takeover News: February Opens With M&A Bang As Gold Miners, REITs Pitch $28 Billion In Deals

Catalent (NYSE: CTLT ), which manufactures pharmaceutical products, is soaring more than 20% in early trading today. Over the weekend, Bloomberg reported that Danaher (NYSE: DHR ) is potentially interested in acquiring the company.

Why Is Catalent (NYSE:CTLT) Stock Up 20% Today?

Catalent (CTLT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Catalent (CTLT)

Catalent stock launched higher Monday on a rumor that Danaher could acquire it in a bid to compete with Thermo Fisher Scientific. The post Catalent Hits Four-Month High As Danaher Reportedly Mulls A Takeover appeared first on Investor's Business Daily.

Catalent Hits Four-Month High As Danaher Reportedly Mulls A Takeover

After two major healthcare and life sciences deals at the end of 2022, M&A in the industry could be about to rebound.

Catalent Stock Surges on Report of Danaher Interest

Life Sciences Company Danaher Corp. DHR, -0.31% is interested in taking over contract manufacturer Catalent Inc. CTLT, -1.04% and is willing to pay a significant premium for the company, Bloomberg reported Monday, citing people familiar with the matter. It's unclear whether Catalent is receptive, the people said, adding that a deal is not imminent.

News for Catalent Stock (CTLT)